Generally, platelets begin to rise after 1-2 weeks of oral administration of Eltrombopta, and therapeutic effects begin to appear. Eltrombopar is a small molecule agonist of platelet production and the platelets in the body start to rise gradually after 1-2 weeks of oral administration of the drug. Therefore, the drug is mainly to elevate platelets, especially for patients with idiopathic thrombocytopenic purpura who are treated with glucocorticoids or immunoglobulins and produce low or little response, as well as thrombocytopenia caused by chemotherapeutic drugs with oncology, can be treated with Etripopat. The use of Eltrombopta must be careful to choose to take it on an empty stomach or between meals, with an interval of 2 hours, and try to maintain an empty stomach. Because Eltrombopar and food calcium ions, iron ions, aluminum ions, magnesium ions, etc. may occur complexation reaction, resulting in reduced bioavailability and poor absorption later. Eltrombopar should be swallowed intact, not crushed and mixed into liquid or juice, and must be swallowed intact. More patients are prone to hepatotoxicity in drug use, so it should be monitored.